NYSEARCA:GERM

ETFMG Treatments Testing and Advancements ETF Stock Forecast, Price & News

$43.44
+0.55 (+1.28 %)
(As of 09/21/2021 12:00 AM ET)
Add
Today's Range
$42.96
$43.61
50-Day Range
$37.38
$45.54
52-Week Range
$26.08
$46.06
Volume8,748 shs
Average Volume21,211 shs
Market Capitalization$60.82 million
P/E RatioN/A
Dividend Yield0.79%
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive GERM News and Ratings via Email

Sign-up to receive the latest news and ratings for ETFMG Treatments Testing and Advancements ETF and its competitors with MarketBeat's FREE daily newsletter.

Basic Details

Issuer ETF Managers Group
Fund NameETFMG Treatments Testing and Advancements ETF
Tax ClassificationRegulated Investment Company
SymbolNYSEARCA:GERM
Inception Date6/17/2020
Fund ManagerSamuel Masucci, Frank Vallario, Donal A. Bishnoi, Devin Ryder
WebN/A
PhoneN/A

Fund Focus

Asset ClassEquity
BenchmarkPrime Treatments, Testing and Advancements Index
CategoryStrategy
FocusTheme
Development LevelBlended Development
RegionGlobal

Fund Statistics

Assets Under Management$66.65 million
Average Daily Volume$0.00
Discount/Premium0.00%

ETF Expenses

Management Fee0.68%
Other Expenses0.00%
Total Expenses0.68%
Fee Waiver0.00%
Net Expenses0.68%

Administrator, Advisor and Custodian

AdministratorU.S. Bancorp Fund Services, LLC
AdvisorETF Managers Group, LLC
CustodianU.S. Bank, N.A.
DistributorETFMG Financial LLC
Transfer AgentU.S. Bank, N.A.
Trustee
Lead Market Maker

Geographic Exposure of GERM

Currency Exposure of GERM

Sector Exposure of GERM

Industry Exposure of GERM

speech bubbles
speech bubbles











ETFMG Treatments Testing and Advancements ETF (NYSEARCA:GERM) Frequently Asked Questions

What stocks does MarketBeat like better than ETFMG Treatments Testing and Advancements ETF?

Wall Street analysts have given ETFMG Treatments Testing and Advancements ETF a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ETFMG Treatments Testing and Advancements ETF wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Is ETFMG Treatments Testing and Advancements ETF a good dividend stock?

ETFMG Treatments Testing and Advancements ETF pays an annual dividend of $0.34 per share and currently has a dividend yield of 0.79%.
View ETFMG Treatments Testing and Advancements ETF's dividend history.

What other stocks do shareholders of ETFMG Treatments Testing and Advancements ETF own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ETFMG Treatments Testing and Advancements ETF investors own include Village Farms International (VFF), Charlotte's Web (CWBHF), 3 Sixty Risk Solutions (PTVYF), (APHA), Inovio Pharmaceuticals (INO), Moderna (MRNA), PayPal (PYPL), AbbVie (ABBV), Brookfield Property Partners (BPY) and Auxly Cannabis Group (CBWTF).

What is ETFMG Treatments Testing and Advancements ETF's stock symbol?

ETFMG Treatments Testing and Advancements ETF trades on the New York Stock Exchange (NYSE)ARCA under the ticker symbol "GERM."

How do I buy shares of ETFMG Treatments Testing and Advancements ETF?

Shares of GERM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ETFMG Treatments Testing and Advancements ETF's stock price today?

One share of GERM stock can currently be purchased for approximately $43.44.

How much money does ETFMG Treatments Testing and Advancements ETF make?

ETFMG Treatments Testing and Advancements ETF has a market capitalization of $60.82 million.


This page was last updated on 9/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.